Table of Contents
2021. View abstract. Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020 Jan 8. View abstract. Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
2019;236(9):2713-2724. View abstract. Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, Mc, Gregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186. View abstract. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. The dose-dependent analgesic effects, abuse liability, safety and tolerability of oral cannabidiol in healthy humans.
2021. View abstract. Aviello G, Romano B, Borrelli F, et al. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 2012;90(8):925-34. View abstract. Baranowska-Kuczko M, Kozlowska H, Kloza M, et al. Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension.
View abstract. Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion. Cureus. 2020;12(4):e7688. View abstract. Bebee B, Taylor DM, Bourke E, et al. The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med J Aust.
View abstract. Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS Drugs. 2020;34(6):661-672. View abstract. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
View abstract. Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020. Am J Emerg Med. 2021;48:218-223. View abstract. Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
2019 Aug;60(8):1586-1592. View abstract. Bisogno T, Di Marzo Y. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 2008;14(23):2299-3305. View abstract. Bloomfield MAP, Green SF, Hindocha C, et al. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.
2020;34(9):981-989. View abstract. Bolsoni LM, Crippa JAS, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology (Berl) 2022. View abstract. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online.
View abstract. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View abstract. Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45(6):1323-31. View abstract. Brady CM, Das, Gupta R, Dalton C, et al.
Mult Scler 2004;10(4):425-33. View abstract. Campos AC, Guimaraes FS. Activation of 5HT1A receptors mediates the anxiolytic effects of cannabidiol in a PTSD model. Behav Pharmacol 2009;20:S54. Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367(1607):3364-78.
Cannabidiol Now Showing Up In Dietary Supplements. Natural Medicines Web site. https://naturalmedicines. therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements. aspx. (Accessed May 31, 2015). Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med.
View abstract. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 1981;21(8-9 Suppl):417S-27S. View abstract. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973;25(8):664-5. View abstract. Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I.
Pharmaceuticals (Basel) 2021;14(9):863. View abstract. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63(7):1245-50. View abstract. Carvalho RK, Rocha TL, Fernandes FH, et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity.
View abstract. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory effect on marble-burying behavior: involvement of CB1 receptors. Behav Pharmacol 2010;21(4):353-8. View abstract. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020. View abstract.
Table of Contents
Latest Posts
Confidential & Accurate A Case Report - Fulltext - Medical Cannabis And ...in Vancouver-Washington
Discreet Best Cbd For Parkinson S - Norfolk Kitchen & Bathin Boise-Idaho
in Minneapolis-Minnesota
All Categories
Navigation
Latest Posts
Confidential & Accurate A Case Report - Fulltext - Medical Cannabis And ...in Vancouver-Washington
Discreet Best Cbd For Parkinson S - Norfolk Kitchen & Bathin Boise-Idaho
in Minneapolis-Minnesota